October Upside Ranks

Business

How far the business inflection is demonstrated today, not source completeness.

• A — Broad, realized commercial growth or earnings; not just a plan.
• B — Real but early, concentrated or mixed operating traction.
• C — Primarily clinical/development or capacity optionality; limited realized economics.
• D — Retained facts undermine the proposed business inflection.

Catalyst

Specificity, observability and timing of a thesis-changing test inside the original window, not its chance of success.

• A — A scheduled or explicitly windowed material readout, launch or commercial ramp; repeated hard operating tests may qualify.
• B — Concrete delivery, orders or earnings tests, but diffuse timing or less discrete thesis change.
• C — A real milestone with important acceptance/economics/timing gaps.
• D — No supported material in-window test.

Target path

Burden of reaching THIS tier target from the dated baseline; not an absolute odds estimate.

• A — Comparatively direct earnings/recognition bridge in retained evidence; still conditional.
• B — Recognizable bridge, but meaningful premium, execution or share-claim sensitivity.
• C — Speculative extension or binary rerating beyond established economics; small-base elasticity is not a forecast.
• D — Exceptional leap far beyond retained cases, with major scale/valuation/financing obstacles.

No bell curve, numeric weights, A+ grades, probability conversion or grade-based reranking. Same rubric for incumbents and additions; target-path grades vary by tier. A catalyst can fail. No synchronized chart grading because technical coverage is not comparable across all 19.

Assessment October 6 of retained evidence, not an October 6 source refresh. Baseline October 1; existing remaining touch window October 4, 2026 to exclusive October 1, 2027. Original source cutoff October 3; additions retrieved October 4; Bloom narrative retrieved October 5 UTC. Original publication dates remain attached to sources.

Original conservative research grades remain in each full story. Partial financial underwriting remains partial: completed qualitative grades do not certify current cash, target dilution, clinical efficacy or funded forecasts. No chart grade is invented from unmatched technical snapshots.